A randomised, double-blind, dose escalating study in healthy volunteers to assess the safety, tolerability, extra pulmonary pharmacodynamics and pharmacokinetics of single doses of GSK961081 (succinate salt)
Latest Information Update: 11 Oct 2021
At a glance
- Drugs Batefenterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Theravance Biopharma
- 23 Jan 2008 Status changed from initiated to completed, in accordance with clinicaltrials.gov.
- 15 Nov 2007 New trial record.